治疗抗胆碱能谵妄所用药物短缺情况
该研究检索犹他大学药物信息服务(UUDIS)数据库2001年1月至2021年12月的药物短缺数据,分析用于治疗抗胆碱能谵妄(AD)的一线药物(毒扁豆碱和 parenteral 苯二氮䓬类)及二线药物(右美托咪定和非毒扁豆碱类中枢性乙酰胆碱酯酶抑制剂)的短缺情况。共报告26次短缺,所有药物类别中位短缺持续6.0个月,研究期末有4次未解决。右美托咪定是单一药物中最常短缺者,苯二氮䓬类是短缺最常见的药物类别;25次涉及 parenteral 制剂,1次涉及利伐斯的明透皮贴剂。88.5%的短缺涉及仿制药,50%的短缺产品为单一来源,最常见原因是生产问题(27%),92%的短缺在时间上与其他短缺重叠。研究期间后半段短缺频率和持续时间增加。
要点
- 2001年1月1日至2021年12月31日UUDIS共报告26次影响AD治疗药物的短缺,所有药物类别中位短缺持续6.0个月。
- 右美托咪定是单一药物中最常短缺者,苯二氮䓬类是短缺最常见的药物类别。
- 25次短缺涉及 parenteral 制剂,1次涉及利伐斯的明透皮贴剂;88.5%的短缺涉及仿制药,50%的产品为单一来源。
- 最常见短缺原因为生产问题(27%);92%的短缺在时间上与其他短缺重叠,研究期末仍有4次未解决。
- 研究期间后半段短缺频率和持续时间增加,多种不同药物同时短缺可能妨碍替代策略。
适用人群与场景
- 急诊医师常遇到抗胆碱能谵妄(AD)患者,该病由抗胆碱能药物中毒引起,可能危及生命。
处置流程与药物剂量
- 毒扁豆碱和苯二氮䓬类是AD药物治疗的主要手段;右美托咪定和非毒扁豆碱类中枢性乙酰胆碱酯酶抑制剂(如利伐斯的明)也有使用描述。
研究设计与关键结果
- 研究类型为药物短缺数据库分析,数据来自犹他大学药物信息服务(UUDIS)数据库2001年1月至2021年12月,共报告26次影响AD治疗药物的短缺。
- 所有药物类别中位短缺持续6.0个月,研究期末有4次短缺未解决;右美托咪定是单一药物中最常短缺者,苯二氮䓬类是短缺最常见的药物类别。
- 25次短缺涉及 parenteral 制剂,1次涉及利伐斯的明透皮贴剂;88.5%的短缺涉及仿制药,50%的短缺产品为单一来源。
- 最常见短缺原因为生产问题(27%);92%的短缺在时间上与其他短缺重叠;研究期间后半段短缺频率和持续时间增加。
证据类型、等级与局限
- 证据类型:基于UUDIS数据库的药物短缺数据分析;局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,医疗保健利益相关者必须在短缺时期制定创新的患者和机构特异性解决方案,并努力在医疗产品供应链中建立韧性,以尽量减少未来用于治疗AD的药物短缺。
- 多种不同药物同时短缺可能妨碍替代作为缓解短缺的手段。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Antimuscarinic delirium (AD), a potentially life-threatening condition frequently encountered by emergency physicians, results from poisoning with antimuscarinic agents. Treatment with physostigmine and benzodiazepines is the mainstay of pharmacotherapy, and use of dexmedetomidine and non-physostigmine centrally-acting acetylcholinesterase inhibitors (cAChEi) such as rivastigmine has also been described. Unfortunately, these medications are subject to drug shortages which negatively impact the ability to provide appropriate pharmacologic treatment of patients with AD.
METHODS: Drug shortage data were retrieved from the University of Utah Drug Information Service (UUDIS) database from January 2001 through December 2021. Shortages of first-line agents used to treat AD (physostigmine and parenteral benzodiazepines) and second-line agents (dexmedetomidine and non-physostigmine cAChEi) were examined. Drug class, formulation, route of administration, reason for shortage, shortage duration, generic status, and whether the drug was a single-source product (made by only one manufacturer) were extracted. Shortage overlap and median shortage durations were calculated.
RESULTS: Twenty-six shortages impacting drugs used to treat AD were reported to UUDIS from January 1, 2001 to December 31, 2021. Median shortage duration for all medication classes was 6.0 months. Four shortages were unresolved at the end of the study period. The single medication most often on shortage was dexmedetomidine, however benzodiazepines were the most common medication class on shortage. Twenty-five shortages involved parenteral formulations, and one shortage involved the transdermal patch formulation of rivastigmine. The majority (88.5%) of shortages involved generic medications, and 50% of products on shortage were single-source. The most common reported reason for shortage was a manufacturing issue (27%). Shortages were often prolonged and, in 92% of cases, overlapped temporally with other shortages. Shortage frequency and duration increased during the second half of the study period.
CONCLUSION: Shortages of agents used in the treatment of AD were common during the study period and affected all agent classes. Shortages were often prolonged and multiple shortages were ongoing at study period end. Multiple concurrent shortages involving different agents occurred, which could hamper substitution as a means of mitigating shortage. Healthcare stakeholders must develop innovative patient- and institution-specific solutions in times of shortage and work to build resilience into the medical product supply chain to minimize future shortages of drugs used for treatment of AD.
参考来源
- Whitledge JD, Soto P, Glowacki KM, et al. Shortages of agents used to treat antimuscarinic delirium. Am J Emerg Med. 2023. PMID: 36893630. doi:10.1016/j.ajem.2023.02.036
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。